Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and ca...

Full description

Bibliographic Details
Main Authors: Rokhsara Rafii, Timothy E. Albertson, Samuel Louie, Andrew L. Chan
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Pulmonary Medicine
Online Access:http://dx.doi.org/10.1155/2011/257496
id doaj-b6b1751fc62b4c508333f872abb5f1a7
record_format Article
spelling doaj-b6b1751fc62b4c508333f872abb5f1a72020-11-24T23:04:28ZengHindawi LimitedPulmonary Medicine2090-18362090-18442011-01-01201110.1155/2011/257496257496Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary DiseaseRokhsara Rafii0Timothy E. Albertson1Samuel Louie2Andrew L. Chan3Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine and VA Northern California Health Care System, 4150 V Street, Suite 3400, Sacramento, CA 95817, USADivision of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine and VA Northern California Health Care System, 4150 V Street, Suite 3400, Sacramento, CA 95817, USADivision of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine, 4150 V Street, Suite 3400, Sacramento, CA 95817, USADivision of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine and VA Northern California Health Care System, 4150 V Street, Suite 3400, Sacramento, CA 95817, USAChronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and can succumb to social isolation. Smoking cessation is crucial, and pharmacotherapy with bronchodilators is helpful in symptom management. Inhaled corticosteroids may be beneficial in some patients. In addition, pulmonary rehabilitation and palliative care are important components under the right clinical circumstance. This review highlights current guidelines and management strategies for COPD and emphasizes novel pharmacotherapy and minimally invasive (nonsurgical) lung-volume reduction interventions that may prove to be of significant benefit in the future.http://dx.doi.org/10.1155/2011/257496
collection DOAJ
language English
format Article
sources DOAJ
author Rokhsara Rafii
Timothy E. Albertson
Samuel Louie
Andrew L. Chan
spellingShingle Rokhsara Rafii
Timothy E. Albertson
Samuel Louie
Andrew L. Chan
Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
Pulmonary Medicine
author_facet Rokhsara Rafii
Timothy E. Albertson
Samuel Louie
Andrew L. Chan
author_sort Rokhsara Rafii
title Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
title_short Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
title_full Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
title_fullStr Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
title_full_unstemmed Update on Pharmaceutical and Minimally Invasive Management Strategies for Chronic Obstructive Pulmonary Disease
title_sort update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease
publisher Hindawi Limited
series Pulmonary Medicine
issn 2090-1836
2090-1844
publishDate 2011-01-01
description Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic effects, and it is the fourth leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate systemic wasting, features of depression, and can succumb to social isolation. Smoking cessation is crucial, and pharmacotherapy with bronchodilators is helpful in symptom management. Inhaled corticosteroids may be beneficial in some patients. In addition, pulmonary rehabilitation and palliative care are important components under the right clinical circumstance. This review highlights current guidelines and management strategies for COPD and emphasizes novel pharmacotherapy and minimally invasive (nonsurgical) lung-volume reduction interventions that may prove to be of significant benefit in the future.
url http://dx.doi.org/10.1155/2011/257496
work_keys_str_mv AT rokhsararafii updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease
AT timothyealbertson updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease
AT samuellouie updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease
AT andrewlchan updateonpharmaceuticalandminimallyinvasivemanagementstrategiesforchronicobstructivepulmonarydisease
_version_ 1725630214582566912